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Purpose: To identify potential predictive factors of incidental prostate cancer (IPca) in 
patients considering tissue-ablation treatment for benign prostatic hyperplasia (BPH).
Materials and Methods: From the 11 centers, 1,613 men who underwent transurethral 
resection of the prostate (TURP) or open prostatectomy were included. Before surgery, 
prostate biopsy was performed in all patients with prostate-specific antigen (PSA) ≥4.0 
ng/ml or with abnormal digital rectal examination (DRE) findings. The patients with 
prostate cancer preoperatively or with PSA ＞20 ng/ml were excluded. As predictive 
factors of IPca, age, body mass index, PSA, DRE, and transrectal ultrasonography 
(TRUS) findings, including total prostate volume (TPV), transition zone volume (TZV), 
and the presence of hypoechoic lesions, were reviewed. PSA density (PSAD) and PSAD 
in the transition zone (PSAD-TZV) were calculated. 
Results: IPca was diagnosed in 78 patients (4.8%). DRE findings, PSA, and TZV were 
independent predictive factors in the multivariate analysis. In the receiver operating 
characteristic curve analysis of PSA, PSAD, and PSAD-TZV, the area under the curve 
(AUC) was the largest for PSAD-TZV (AUC, 0.685). 
Conclusions: IPca was detected in 4.8% of the population studied. In addition to DRE 
findings, the combination of TZV and PSA can be useful predictive factors of IPca in 
patients considering tissue-ablation treatment as well as TURP. 
Key Words: Prostate neoplasms; Prostatic hyperplasia; Transurethral resection of 
prostate
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial 
License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, 
distribution, and reproduction in any medium, provided the original work is properly cited.
Article History:
received 21 November, 2011
accepted 30 March, 2012
Corresponding Author:
Jin Seon Cho
Department of Urology, Hallym 
University Sacred Heart Hospital, 
Hallym University College of Medicine, 
22 Gwanpyeong-ro, 170beon-gil, 
Dongan-gu, Anyang 431-796, Korea
TEL: +82-31-380-3851
FAX: +82-31-380-3852
E-mail: js315@hallym.or.kr
INTRODUCTION
Transurethral resection of the prostate (TURP) is a stand-
ard surgical treatment for symptomatic benign prostatic 
hyperplasia (BPH). However, it carries risks of potentially 
fatal complications such as profuse bleeding and transure-
thral resection syndrome. Recently, photoselective vapor-
ization of the prostate (PVP) with a high-performance po-
tassium titanyl phosphate (KTP) laser was introduced as 
a minimally invasive surgery for BPH. PVP is associated 
with a significantly shorter hospital stay and urethral 
catheter indwelling time and significantly lower blood loss 
during the operation than is conventional TURP [1,2]. 
Thus, PVP has become a popular surgical treatment mo-Korean J Urol 2012;53:391-395
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TABLE 1. Characteristics of the patients with incidental prostate 
cancer after surgical treatment for benign prostatic hyperplasia
Characteristic
cT1a 
(n=32, 41%)
cT1b 
(n=46, 59%)
Total 
(n=78)
Gleason score
≤6
7
≥8
High-risk 
prostate cancer
a
Age ＞75 yr
Age ≤75 yr
25 (81.3)
  4 (12.5)
  2 (6.2)
  9 (15.3)
b
  3 (33.3)
  6 (66.6)
15 (31.7)
11 (23.9)
20 (44.4)
35 (44.8)
b
  8 (22.9)
27 (77.1)
40 (51.2)
15 (19.2)
22 (28.2)
44 (56.4)
b
11 (25.0)
33 (75.0)
Values are presented as number (%).
PSA, prostate-specific antigen.
a:PSA ≥10 ng/ml or Gleason score ≥7, 
b:% from total number of 
incidental prostate cancer.
dality for BPH with outcomes comparable to TURP but 
with fewer complications [1].
In the past, incidental prostate cancers detected after 
TURP accounted for 1.5 to 15% of all prostate cancers, but 
the number of cases has been decreasing since the in-
troduction of prostate-specific antigen (PSA) testing in the 
screening of prostate cancer [3]. Although most of the in-
cidental prostate cancers were considered to be clinically 
insignificant [4], recent studies have suggested that with 
increasing tumor volume, especially of T1b cancers, the 
clinical course becomes more unfavorable and is com-
parable with that of T2 tumors [5,6].
With the recent increase in the performance of laser abla-
tion of the prostate, undiagnosed prostate cancer may be-
come an important issue. However, the risk of missing pros-
tate cancer during PVP has rarely been investigated. We 
therefore attempted to extrapolate the incidence of in-
cidental prostate cancer and to analyze its predictive fac-
tors during PVP by means of a retrospective review of con-
temporary TURP. 
MATERIALS AND METHODS
The medical records of 1,613 men who underwent TURP 
or open prostatectomy in 11 medical centers between 2004 
and 2008 were reviewed. Before surgery, prostate biopsy 
was performed in all patients with PSA ≥4.0 ng/ml or with 
abnormal digital rectal examination (DRE) findings. 
Patients who were diagnosed as having prostate cancer, 
high-grade prostate intraepithelial neoplasia, or atypical 
small acinar proliferation by biopsy were excluded. Also, 
those with PSA ≥20 ng/ml were excluded irrespective of 
their biopsy results. Mean resected prostate volume was 
18.8±16.5 g. According to the volume of cancer in the re-
sected chips, incidental prostate cancer was staged as clin-
ical stage T1a (cancer volume ＜5% of total chips) or clinical 
stage T1b (cancer volume ≥5% of chips). High-risk pros-
tate cancer was defined as such: PSA ≥10 ng/ml or Gleason 
score ≥7 [7,8]. As potential predictive factors of incidental 
prostate cancer, age, body mass index, PSA, DRE findings, 
and transrectal ultrasonography (TRUS) findings, includ-
ing total prostate volume (TPV), transition zone volume 
(TZV), and the presence of hypoechoic lesions, were 
reviewed. PSA density (PSAD, PSA/TPV) and PSAD in the 
transition zone (PSAD-TZV, PSA/TZV) were calculated to 
evaluate their clinical usefulness in predicting incidental 
prostate cancer. 
The patients were divided into two groups according to 
the final pathologic results after surgery: the BPH group 
and the incidental prostate cancer group. Univariate and 
multivariate analyses of the clinical factors were per-
formed for comparison between the two groups. Receiver 
operating characteristic (ROC) curve analysis was used to 
evaluate the performance of PSA-related values such as 
PSA, PSAD, and PSAD-TZV as predictors of incidental 
prostate cancer.
RESULTS
The mean age of the patients was 71.2 years (range, 41 to 
80 years) and their mean serum PSA was 4.8±4.3 ng/ml. 
TURP and open prostatectomy were performed in 1,528 
and 85 patients, respectively. Seventy-eight patients 
(4.8%) had incidental prostate cancer diagnosed after 
surgery. Among the patients with PSA ≤4.0 ng/ml, pros-
tate cancer was diagnosed in 3.7%. The number of patients 
with clinical stage T1a and T1b cancer was 32 (41.0%) and 
46 (59.0%), respectively, and the proportion of prostate can-
cer with a Gleason score of 7 or higher was 47.4%. Clinically 
high-risk cancer accounted for 56.4% of the incidental pros-
tate cancer (Table 1). The treatment received by these pa-
tients included androgen deprivation treatment (42.3%), 
watchful waiting (25.6%), radical prostatectomy (15.4%), 
and radiation therapy (6.4%), and 6.1% of patients were 
transferred to another hospital. In the univariate analysis, 
DRE findings (p＜0.001), TRUS findings (p=0.006), PSA 
(p=0.001), and TZV (p＜0.001) were significant predictors 
of incidental prostate cancer (Table 2). In the multivariate 
analysis, DRE findings (p=0.001), PSA (p＜0.001), and 
TZV (p=0.002) were independent predictive factors of in-
cidental prostate cancer (Table 3). In the ROC curve analy-
sis of PSA, PSAD, and PSAD-TZV, the area under the curve 
(AUC) was the largest for PSAD-TZV (AUC, 0.685; Fig. 1) 
with a cutoff value of 0.17 ng/ml/cc (sensitivity, 66.7%; spe-
cificity, 62.5%). Prostate cancer was diagnosed in 8.1% of 
the patients with PSAD-TZV ≥0.17 ng/ml/ml and in 3.0% 
of the others (p=0.001).
DISCUSSION
The present study raises several important issues that 
need to be addressed. 
First, this report on the contemporary incidence of pros-
tate cancer among patients undergoing TURP is, to our 
knowledge, the most recent and the second largest of the Korean J Urol 2012;53:391-395
Clinical Impact of Incidental Prostate Cancer 393
TABLE 2. Univariate analysis of the clinical factors of the 
patients with BPH for detecting incidental prostate cancer
BPH Prostate cancer p-value
DRE findings
Normal 
Abnormal 
TRUS findings
Normal
Abnormal
PSA groups 
(ng/ml)
0-4 
4-10 
10-20 
Age (yr) 
BMI (kg/m
2) 
PSA (ng/ml) 
TPV in TRUS 
(ml) 
TZV in TRUS 
(ml) 
1,001 (96.3)
   146 (86.9)
1,098 (96.3)
   170 (90.9)
   875 (96.3)
   474 (95.8)
   186 (89.0)
71.1±7.6
23.7±3.2
  4.7±4.2
  59.5±30.5
  32.4±24.4
38 (3.7)
22 (13.1)
42 (3.7)
17 (9.1)
34 (3.7)
21 (4.2)
23 (11.0)
72.4±7.5
24.2±2.7
  6.9±5.4
  54.4±31.5
  22.8±12.9
＜0.001
a
   0.006
a
＜0.001
a
   0.151
b
   0.139
b
   0.001
b
   0.196
b
＜0.001
b
Values are presented as number (%) or mean±SD.
BPH, benign prostatic hyperplasia; DRE, digital rectal exam; 
BMI, body mass index; PSA, prostate-specific antigen; TPV, total 
prostate volume; TRUS, transrectal ultrasonography; TZV, tran-
sitional zone volume.
a:Chi-square test, 
b:Independent student t-test.
TABLE 3. Multivariate analysis of the clinical factors of patients 
with BPH for predicting incidental prostate cancer
p-value
a HR 95% CI
Age 
BMI
DRE findings 
TRUS findings
PSA 
TPV in TRUS
TZV in TRUS
0.142
0.295
0.001
0.110
＜0.001
0.297
0.002
1.031
1.056
3.229
1.856
1.033
1.011
0.945
0.990-1.073
0.953-1.170
1.587-6.572
0.870-3.962
1.016-1.051
0.990-1.033
0.911-0.980
BPH, benign prostatic hyperplasia; HR, hazard ratio; CI, con-
fidence interval; BMI, body mass index; DRE, digital rectal exam; 
PSA, prostate-specific antigen; TPV, total prostate volume; 
TRUS, transrectal ultrasonography; TZV, transitional zone 
volume.
a:Calculated by logistic regression analysis.
FIG. 1. Receiver operating characteristic curve analysis of 
prostate-specific antigen (PSA), PSA density (PSAD), and 
PSAD-in transition zone volume (PSAD-TZV) on risk of inci-
dental prostate cancer in the patients who underwent surgical 
treatment for benign prostatic hyperplasia. AUC, area under 
the curve; CI, confidence interval.
kind reported recently. Several studies have compared the 
incidence of incidental prostate cancer among patients un-
dergoing TURP between the pre-PSA era and the PSA era 
and have shown a decrease in incidental prostate cancer 
from 15 to 23% to 4 to 6% [9,10]. Most recently, Melchior 
et al. [11] showed a 5.4% incidence of prostate cancer in 
1,931 patients who underwent TURP after a thorough pre-
operative screening for prostate cancer. In the present 
study, the incidence of incidental prostate cancer was 4.8%, 
and among these cases, cT1a and cT1b prostate cancer were 
detected in 2.0% and 2.8%, respectively. Our result is sim-
ilar to reports by others and shows that the risk of missing 
undiagnosed prostate cancer is omnipresent during laser 
ablation of the prostate [12]. However, the actual risk of 
missing prostate cancer by laser ablation of the prostate 
has rarely been investigated. Only two reports have ad-
dressed this issue. Ruszat et al. [13] reported the largest 
series of data on patient follow-up after PVP. By doing thor-
ough preoperative investigation using PSA and DRE in all 
patients and at least 2 transrectal biopsies in the case of 
an abnormal PSA or DRE result, they were able to keep the 
subsequent prostate cancer rate at a very low level of 1.2%. 
The results reported by Malek et al. [14] are more realistic, 
with a 5% cancer detection rate at subsequent follow-up af-
ter PVP. 
The second issue is whether the cancer diagnosed in-
cidentally during TURP is significant. In previous Western 
studies, the proportion of cancers with a Gleason score of 
7 or higher in radical prostatectomy specimens from T1a 
and T1b cancers was reported to be 0 to 15% and 9.8 to 64%, 
respectively [15-17]. Also, T1a cancer was more likely to be 
organ-confined than was T1b cancer, and in terms of patho-
logical stage at radical prostatectomy and progression, T1b 
was closer to T1c than to T1a [10]. According to Melchior 
et al. [11], 79% of their incidental cancers discovered during 
TURP were T1a, and only 21% were T1b. Twenty-five per-
cent of these patients underwent subsequent radical pros-
tatectomy, all of them having either pathologically or-
gan-confined or pT0 cancer. The results of our study look 
more alarming, with more than half of patients having T1b Korean J Urol 2012;53:391-395
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or high-risk cancer. Also, most of our patients needed an 
active treatment although the indication for choosing an 
active treatment could not be clearly explained in all cases. 
The reason for the relatively high percentage of T1b and 
high-risk cancers in our patients is unknown but may need 
to be discussed. First, the patients in this study were drawn 
from the population in Korea where a PSA screening pro-
gram is not established. This may have resulted in a higher 
stage and cancer volume at diagnosis. Another reason 
might be the generally worse histological findings observed 
in Eastern patients compared with Western. In a Korean 
population-based study that reviewed the data of patients 
with prostate cancer by PSA screening, prostate cancer 
with a Gleason score of 7 or higher was diagnosed in 46.1%, 
which was higher than in the Western population [18].
Third, can we predict incidental prostate cancer by use 
of preoperative parameters? Interestingly, this study dem-
onstrated that PSAD-TZV proved to be more useful than 
PSA density or PSA alone. The concept of PSAD-TZV has 
been reported as one of the parameters for improving the 
diagnostic accuracy of extended-field biopsy or re-biopsy in 
patients with gray-zone PSA [19-21]. Even though we take 
into account that the prostate volume measured by TRUS 
is more accurate in smaller glands [22], the PSAD-TZV 
might also be regarded as a useful parameter for predicting 
incidental prostate cancer among patients who are plan-
ning to undergo surgical treatment for BPH. Free PSA and 
complexed PSA, which were not included in the analysis 
in the present study, can be considered as additional pre-
dictive parameters of incidental prostate cancer. Froehner 
et al. [23] reported that derivatives of prostate-specific an-
tigen, such as percentage free PSA or complexed PSAD, 
were more useful than total PSA for predicting incidental 
prostate cancer. However, they did not include the TZV in 
their analysis. It is unclear whether the clinical stage of in-
cidental prostate cancer can predict progression of prostate 
cancer, for a hard endpoint such as disease-specific surviv-
al required too long a follow-up time to be evaluated. 
Therefore, it is difficult to select the optimal candidate for 
aggressive treatment among patients with T1a-T1b pros-
tate cancer [24]. In a limited study, not the stage but PSA 
before and after surgery and Gleason score were predictive 
factors of disease progression for incidental prostate can-
cer [15]. On that basis, we defined high-risk prostate cancer 
as a Gleason score of 7 or higher or preoperative PSA of 10 
ng/ml or higher, and by applying the age of 75 years as the 
upper limit for definite treatment, the proportion of pa-
tients who needed definite treatment for incidental pros-
tate cancer was only 2.0% (33 of 1613; Table 1). 
The present study has several limitations to be 
discussed. We did not observe the emergence of prostate 
cancer after TURP in a prospective manner and we did not 
evaluate the disease progression or survival of the patients 
with incidental prostate cancer. A relatively high pro-
portion of patients underwent imperative TURP owing to 
recurrent acute urinary retention, infection, or other rea-
sons, so that efforts to screen prostate cancer might have 
been inadequate. For instance, DRE was not performed in 
26% of patients, which may have led to TURP not being per-
formed in a significant number of patients with palpable 
prostate cancer. We cannot expect our results to apply to 
all PVP patients, because patients undergoing PVP and 
TURP may represent different populations. For example, 
PVP patients may be prescreened to include patients with 
a relatively younger age, lower prostate volume, and lower 
PSA than TURP patients. A study comparing the accuracy 
of PSAD-TZV with that of percentage free PSA or com-
plexed PSAD in detecting incidental prostate cancer is also 
needed.
In many recent studies, KTP laser ablation has been 
proved to be a minimally invasive surgical treatment for 
BPH with comparable efficacy and less morbidity than 
TURP. Even if the proportion of patients with incidental 
prostate cancer who need definite treatment is small, an 
unfavorable pattern was demonstrated in Korean 
patients. To increase the accuracy of detection of prostate 
cancer in biopsy, PSA, DRE findings, and transition zone 
might be used as predictive parameters before surgical 
treatment for BPH, especially before laser ablation 
treatment. For patients with a high PSAD-TZV, ex-
tended-core or saturated prostate biopsy could be 
recommended. In addition, even though a prostate biopsy 
may have a negative result for cancer, patients should be 
informed of the possibility of emerging prostate cancer in 
the future. The results of this study may be additional evi-
dence of the usefulness of PSAD-TZV for improving the ac-
curacy of prostate biopsy. 
CONCLUSIONS
Incidental prostate cancer was detected in 4.8% of the pa-
tients who underwent surgical treatment for BPH and 
more than half of them showed clinically significant pros-
tate cancer. In addition to DRE findings, a combination of 
TZV and PSA can be used as useful predictive factors of in-
cidental prostate cancer in patients considering tis-
sue-ablation treatment as well as TURP.
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